Mirabegron

🧮 Dose calculator

Overactive bladder · Regimen source: FDA Myrbetriq · 2.2

• • With solifenacin: mirabegron 25 mg + solifenacin 5 mg. FDA Myrbetriq · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Myrbetriq · 8.1

  “Risk Summary There are no studies with the use of MYRBETRIQ/MYRBETRIQ Granules in pregnant women or adolescents to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Myrbetriq · 8.2

  “Risk Summary There are no data on the presence of mirabegron in human milk, the effects on the breastfed child, or the effects on milk production.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Myrbetriq · 8.4

  “The safety and effectiveness have been established only for the following pediatric indications: • MYRBETRIQ: Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35 kg or more. • MYRBETRIQ Granules: Treatment of neurogenic detrusor overactivity (NDO) in …”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Myrbetriq · 8.5

  “No overall differences in safety or effectiveness were observed between patients younger than 65 years of age and those 65 years of age or older in these studies.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.